$100M market cap for a P3 asset is still, by market valuations, incredible value IMO. NEU does have ‘more drugs/ indications’ but I believe than DXB but potentially FSGS has larger market potential. Very pleased with our performance over the last few weeks. I’m sure vindicating for those who were doubting themselves that we weren’t crazy and the rest of the market was - one of which was me.
2024 will determine whether the drug can be registered in 2025. If everything goes well, it will be a billion dollar company
$100M market cap for a P3 asset is still, by market valuations,...
-
- There are more pages in this discussion • 885 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26318 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 170072 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |